Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3064572 | Journal of Neuroimmunology | 2011 | 8 Pages |
Abstract
Although therapy for multiple sclerosis (MS) has changed substantially over the past few decades, introducing immunomodulatory drugs into everyday clinical practice, it is still not satisfactory enough in halting the disease progression and increasing disability. Moreover, its injection-based administration leads to suboptimal adherence, even further reducing the potential treatment benefits. Emerging disease-modifying oral agents for MS are therefore warranted. In this paper advances in the novel oral therapeutic approaches to MS treatment are reviewed.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Jacek Losy, Alicja Kalinowska-Łyszczarz,